Chris O’Donnell
Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation @ Pfizer
Chris O’Donnell is a Series A investor at Pfizer focused on Biotechnology and Mobile. Chris O’Donnell is the Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation at Pfizer. Chris O'Donnell attended UC Irvine.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Chris O’Donnell invests in
Stages Chris O’Donnell invests in
Countries Chris O’Donnell invests in
Investment Focus
Industry
- Biotechnology 2 (50%)
- Mobile 1 (25%)
- Hardware 1 (25%)
- Software 1 (25%)
- Biopharma 1 (25%)
Stage
- Series A 2 (50%)
- Series B 2 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Triana Biomedicines
|
Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. | $120M / Series B / Dec 03, 2025 | |
Somewear Labs
|
Somewear is a satellite communications solution designed for the increasingly digital world. Somewear is building a satellite-powered platform to keep people safe. Somewear gives any remote operative a reliable line to safety and keeps organizations compliant at a fraction of the traditional cost with a combination of compact satellite hotspots andsoftware designed for low-bandwidth applications.It was founded in 2017 and is based in San Francisco, California. | $13.7M / Series A / Sep 22, 2022 | |
|
Triana Biomedicines
|
Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. | $110M / Series A / Apr 06, 2022 | |
Pyxis Oncology
|
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer. The company has engaged in deep analyses of tumor antigen-specific tumor-infiltrating lymphocytes (TILs) within hot tumors and of tumor cell signaling pathways within cold tumors, providing laboratories with development of novelantibody-based immunotherapies.It was founded in 2019 and is based in Boston, Massachusetts. | $152M / Series B / Mar 30, 2021 |
Co-Investors
About Pfizer
Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.
Pfizer Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alessandra Leone
Global CMC Sr. Manager
|
|||
|
Angela L Coral
Senior Manager, Partnerships & Impact Reporting, Global Health & Social Impact
|
|||
Barbara Dalton
Senior Managing Partner, Pfizer Ventures; VP, Worldwide Business Development
|
|||
Chris Boshoff
CSO
|
|||
|
Chris O’Donnell
Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chris O’Donnell invest in?
Chris O’Donnell invests primarily in Biotechnology, Mobile and Hardware startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Chris O’Donnell last invest?
The most recent investment recorded for Chris O’Donnell closed in Dec 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
